A case report on the long-term survival of a patient with HER2-positive metastatic gastric adenocarcinoma and a short review of the current literature

被引：1
作者：
Puhr, Hannah Christina [1 ,2 ]
Ilhan-Mutlu, Ayseguel [1 ,2 ]
机构：
[1] Med Univ Vienna, Div Oncol, Dept Med 1, Vienna, Austria
[2] Med Univ Vienna, Upper Gastrointestinal Tumors Unit, Comprehens Canc Ctr Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2020年 / 13卷 / 04期
关键词：
Gastric cancer; Upper GI cancer; HER2; Trastuzumab; Ramucirumab; GASTROESOPHAGEAL JUNCTION CANCER; HER2; STATUS; OPEN-LABEL; TRASTUZUMAB; CHEMOTHERAPY; ESOPHAGEAL; PROGNOSIS;
D O I：
10.1007/s12254-020-00649-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The prognosis of patients with metastatic gastroesophageal cancer remains poor despite numerous promising clinical trials, and the clinical benefit of systemic therapies is under critical review. This case report of a patient with human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric adenocarcinoma is an impulse for the importance of individual decision making and molecular guided treatment options.
引用
收藏
页码：453 / 458
页数：6
相关论文
共 32 条
  • [1] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
    Al-Batran, Salah-Eddin
    Homann, Nils
    Pauligk, Claudia
    Goetze, Thorsten O.
    Meiler, Johannes
    Kasper, Stefan
    Kopp, Hans-Georg
    Mayer, Frank
    Haag, Georg Martin
    Luley, Kim
    Lindig, Udo
    Schmiegel, Wolff
    Pohl, Michael
    Stoehlmacher, Jan
    Folprecht, Gunnar
    Probst, Stephan
    Prasnikar, Nicole
    Fischbach, Wolfgang
    Mahlberg, Rolf
    Trojan, Joerg
    Koenigsmann, Michael
    Martens, Uwe M.
    Thuss-Patience, Peter
    Egger, Matthias
    Block, Andreas
    Heinemann, Volker
    Illerhaus, Gerald
    Moehler, Markus
    Schenk, Michael
    Kullmann, Frank
    Behringer, Dirk M.
    Heike, Michael
    Pink, Daniel
    Teschendorf, Christian
    Loehr, Carmen
    Bernhard, Helga
    Schuch, Gunter
    Rethwisch, Volker
    von Weikersthal, Ludwig Fischer
    Hartmann, Joerg T.
    Kneba, Michael
    Daum, Severin
    Schulmann, Karsten
    Weniger, Joerg
    Belle, Sebastian
    Gaiser, Timo
    Oduncu, Fuat S.
    Guentner, Martina
    Hozaeel, Wael
    Reichart, Alexander
    [J]. LANCET, 2019, 393 (10184) : 1948 - 1957
  • [2] Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).
    Alsina, Maria
    Tabernero, Josep
    Shitara, Kohei
    Doi, Toshihiko
    Dvorkin, Mikhail
    Mansoor, Wasat
    Arkenau, Hendrik-Tobias
    Prokharau, Aliaksandr
    Ghidini, Michele
    Faustino, Catia
    Gorbunova, Vera
    Zhavrid, Edvard
    Nishikawa, Kazuhiro
    Ando, Takayuki
    Yalcin, Suayib
    Van Cutsem, Eric
    Skanji, Donia
    Leger, Catherine
    Sabater, Javier
    Ilson, David H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] [Anonymous], 2019, SEER CANC STAT FACTS
  • [4] Bang YJ, 2010, LANCET, V376, P1302
  • [5] A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study
    Bang, Yung-Jue
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [6] ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
    Cherny, N. I.
    Sullivan, R.
    Dafni, U.
    Kerst, J. M.
    Sobrero, A.
    Zielinski, C.
    Piccart, M. J.
    Bogaerts, J.
    Tabernero, J.
    Latino, N. J.
    de Vries, E. G. E.
    [J]. ESMO OPEN, 2016, 1 (05)
  • [7] Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study
    De Vita, Ferdinando
    Borg, Christophe
    Farina, Gabriella
    Geva, Ravit
    Carton, Iris
    Cuku, Hera
    Wei, Ran
    Muro, Kei
    [J]. FUTURE ONCOLOGY, 2019, 15 (23) : 2723 - 2731
  • [8] Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer
    Fu, Xiaomin
    Zhang, Yong
    Yang, Jing
    Qi, Yalong
    Ming, Yue
    Sun, Miaomiao
    Shang, Yiman
    Yang, Yonghao
    Zhu, Xiaoyan
    Gao, Quanli
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 6091 - 6100
  • [9] Optimal regimen of trastuzumab in combination with oxaliplatin/capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
    Gong, Jifang
    Liu, Tianshu
    Fan, Qingxia
    Bai, Li
    Bi, Feng
    Qin, Shukui
    Wang, Jinwan
    Xu, Nong
    Cheng, Ying
    Bai, Yuxian
    Liu, Wei
    Wang, Liwei
    Shen, Lin
    [J]. BMC CANCER, 2016, 16
  • [10] Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial
    Hecht, J. Randolph
    Bang, Yung-Jue
    Qin, Shukui K.
    Chung, Hyun C.
    Xu, Jianming M.
    Park, Joon O.
    Jeziorski, Krzysztof
    Shparyk, Yaroslav
    Hoff, Paulo M.
    Sobrero, Alberto
    Salman, Pamela
    Li, Jin
    Protsenko, Svetlana A.
    Wainberg, Zev A.
    Buyse, Marc
    Afenjar, Karen
    Houe, Vincent
    Garcia, Agathe
    Kaneko, Tomomi
    Huang, Yingjie
    Khan-Wasti, Saba
    Santillana, Sergio
    Press, Michael F.
    Slamon, Dennis
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (05) : 443 - +
1234